Biomimesys
Toxicity and efficiency, two pillars of future drugs discovery in neurodegenerative deceases
From different studies we know that more than 92% of drug candidates for Central Nervous System diseases fail in clinical trials, with 34% of safety failure. All that candidates have successfully passed in vitro steps and animal testing. Conclusion is straightforward : we have to deeply change biological models in Read more…
